Genmab

This trial tested a new antibody drug called GEN1055, alone or with pembrolizumab (and sometimes chemotherapy), in 21 adults with advanced solid tumors. The goal was to check safety and find the best dose, and to see if the drug could shrink tumors. The study was stopped early, b…

This early-stage trial tested a new antibody called GEN1057 in 23 people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check safety and find the right dose. The trial was terminated early, so results are limited.

This study tested a new drug called GEN3014 in people with blood cancers like multiple myeloma, lymphoma, and leukemia that had returned or stopped responding to treatment. The main goal was to check the drug's safety and find the best dose. About 130 people took part, but the st…

This trial tested a new drug (GEN1042) combined with radiation, with or without another drug (pembrolizumab), in people with advanced solid tumors that had spread and no standard treatment options. The goal was to see if the combination was safe and could shrink tumors, including…

This trial tested a new drug, GEN1078, in people with advanced solid tumors that had stopped responding to standard treatments. The study was stopped early after enrolling only 3 participants. Its main goals were to check for side effects, see how the drug moves through the body,…

This study tested a drug called PRO1160 in people with advanced kidney cancer, nasopharyngeal cancer, or non-Hodgkin lymphoma that had spread or come back after treatment. The goal was to find a safe dose and see if the drug could shrink tumors. The trial was stopped early, so re…

This study tested a new drug, GEN1286, in 23 adults with advanced solid tumors that had spread or could not be removed by surgery. The goal was to check the drug's safety and whether it could shrink tumors. The trial was terminated early, so results are limited.

This early-stage trial tested a new drug called GEN3017 in people with CD30-positive Hodgkin or non-Hodgkin lymphoma that had returned or stopped responding to other treatments. The main goal was to check safety and find the right dose. Only 9 people took part before the study wa…

This study tested a new drug called PRO1107 in 33 people with advanced solid tumors, including ovarian, endometrial, and lung cancers. The goal was to check safety and see if the drug could shrink tumors. The trial was stopped early, so results are limited.

This trial tested a new drug called GEN1047 in 179 people with advanced solid tumors (breast, endometrial, ovarian, or lung cancer) that had stopped responding to standard treatments. The main goals were to check safety, side effects, and how the body processes the drug. The stud…